About: Cabozantinib

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Cabozantinib Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/drugbank/Drug, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	http://linked.opendata.cz/ontology/drugbank/Drug
http://linked.open...gbank/description	Cabozantinib was approved in 2012 and is a non-specific tyrosine kinase inhibitor. It is marketed as COMETRIQ™, which is indicated for the treatment of metastatic medullary thyroid cancer. It's label includes a black box warning of gastrointestinal perforations, fistulas, and hemorrhage. (en)
http://linked.open...y/drugbank/dosage	http://linked.opendata.cz/resource/drugbank/dosage/271B59FB-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/dosage/271B59FC-363D-11E5-9242-09173F13E4C5
http://linked.open...generalReferences	# Durante C, Russo D, Verrienti A, Filetti S: XL184 (cabozantinib) for medullary thyroid carcinoma. Expert Opin Investig Drugs. 2011 Mar;20(3):407-413. doi: 10.1517/13543784.2011.559163. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/21314233 (en)
http://linked.open...gy/drugbank/group	approved (en)
http://linked.open...drugbank/halfLife	Cabozantinib has a long half-life of 55 hours. (en)
http://linked.open...ugbank/indication	For the treatment of metastatic medullary thyroid cancer. (en)
sameAs	Cabozantinib
Title	Cabozantinib (en)
adms:identifier	http://linked.opendata.cz/resource/drugbank/drug/DB08875/identifier/chebi/72317 http://linked.opendata.cz/resource/drugbank/drug/DB08875/identifier/drugbank/DB08875 http://linked.opendata.cz/resource/drugbank/drug/DB08875/identifier/kegg-drug/D10062 http://linked.opendata.cz/resource/drugbank/drug/DB08875/identifier/wikipedia/Cabozantinib
http://linked.open...mechanismOfAction	Cabozantinib inhibits specific receptor tyrosine kinases such as VEGFR-1, -2 and -3, KIT, TRKB, FLT-3, AXL, RET, MET, and TIE-2. (en)
http://linked.open...outeOfElimination	Cabozantinib is eliminated mostly by the feces (54%) and also by the urine (27%). (en)
http://linked.open.../drugbank/synonym	cabozantinib s-malate (en) XL184 (en) BMS 907351 (en) BMS907351 (en) Cabozantinib (S)-malate (en) Cabozantinib L-malate (en) Cometriq (en) XL 184 (en) XL-184 (en)
http://linked.open...drugbank/toxicity	Cabozantinib has a black box warning of serious gastrointestinal fistulas and perforations, and potentially fatal hemoptysis and gastrointestinal hemorrhage. (en)
http://linked.open...umeOfDistribution	The volume of distribution is 349L. (en)
http://linked.open...k/foodInteraction	Avoid grapefruit juice. Combination may increase levels of cabozantinib. Also avoid all other strong CYP3A4 inhibitors. (en)
http://linked.open...nk/proteinBinding	Cabozantinib has extensive plasma protein binding (≥ 99.7%). (en)
foaf:page	http://www.drugs.com/mtm/cabozantinib.html http://www.rxlist.com/cometriq-drug.htm
http://linked.open.../Water-Solubility	http://linked.opendata.cz/resource/drugbank/property/271B59FD-363D-11E5-9242-09173F13E4C5
http://linked.open...l/drug/hasATCCode	http://linked.opendata.cz/resource/atc/L01XE26
http://linked.open...ugbank/absorption	After oral administration, peak plasma concentration was achieved in 2-5 hours. (en)
http://linked.open.../affectedOrganism	Humans and other mammals (en)
http://linked.open...casRegistryNumber	849217-68-1 (en)
http://linked.open...rugbank/clearance	At steady state, the clearance is 4.4 L/hr. (en)

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 39 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software